HKG: 2137 Archives

Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV

November 20, 2024

•

Fineline Cube

China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218), an investigational small interfering ribonucleic acid (siRNA) therapy for chronic hepatitis B virus (HBV) infection. Phase II ENSURE Study Design and Initial FindingsThe active-controlled and randomized Phase II…
Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization

July 31, 2024

•

Fineline Cube

Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its US partner VBI Vaccines Inc. (OTCMKTS: VBIVQ) has commenced bankruptcy reorganization proceedings. Brii Bio has a history of licensing agreements with VBI, securing exclusive global rights to BRII-179 and Asia-Pacific rights to PreHevbri (excluding Japan)…
Brii Biosciences’ BRII-179 Shows Promise in Phase II Trials for Chronic Hepatitis B at EASL 2024

June 11, 2024

•

Fineline Cube

Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has presented new data from two Phase II clinical studies on BRII-179 at the European Association for the Study of the Liver (EASL) 2024 annual conference. The data confirm the efficacy of BRII-179 in combination with BRII-835 or…
Brii Biosciences’ HBV Drug Candidates Receive NMPA’s Breakthrough Therapy Designations

May 14, 2024

•

Fineline Cube

Brii Biosciences Ltd (HKG: 2137) has announced that two of its hepatitis B virus (HBV) drug candidates, BRII-835 (elebsiran) and BRII-877 (tobevibart), have been granted breakthrough therapy designations (BTDs) by China’s National Medical Products Administration (NMPA). BRII-877 (tobevibart) is a hepatitis B virus-specific broad-spectrum neutralizing monoclonal antibody (mAb) designed to…
Brii Biosciences’ BRII-835 Aims for Breakthrough Therapy Status in China for Chronic Hepatitis B

May 9, 2024

•

Fineline Cube

The Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, is poised to secure breakthrough therapy designation (BTD) for its drug BRII-835 (VIR-2218) from the National Medical Products Administration (NMPA). The drug is intended for the treatment of chronic…
Brii Biosciences Acquires VBI Vaccines’ Intellectual Property and Manufacturing Rights in Strategic Deal

February 18, 2024

•

Fineline Cube

Brii Biosciences Ltd (HKG: 2137), based in China, has reached an agreement with US-based VBI Vaccines Inc. to acquire all intellectual property rights to VBI-1901 (BRII-179), along with the manufacturing technologies for BRII-179 and PreHevbrio/PreHevbri. The agreement also grants Brii marketing rights for VBI-1901 in the Asia Pacific region, excluding…
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy

January 4, 2024

•

Fineline Cube

Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the appointment of Dr. Brian Alvin Johns as the firm’s Chief Scientific Officer (CSO), effective from January 3, 2024. In his new role, Dr. Johns will be responsible for overseeing the company’s discovery programs and charting…
Brii Biosciences’ BRII-179 Vaccine on Track for Breakthrough Therapy Designation in China

November 23, 2023

•

Fineline Cube

China’s Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137), a China-based company, is poised to secure breakthrough therapy designation (BTD) status for its BRII-179 (VBI-2601), a first-in-class therapeutic vaccine targeting Pre-S1/Pre-S2/S for the treatment of chronic hepatitis B virus (HBV) infection. The potential designation…